GAITHERSBURG, Md., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax recombinant protein nanoparticle technology and includes Novavax proprietary MatrixM adjuvant.
Todays agreement with Serum Institute enhances Novavax commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents, said Stanley C. Erck, President and Chief Executive Officer of Novavax. We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks.
The agreement with SIIPL augments a global supply chain that will deliver over two billion doses of NVX-CoV2373 annually as of 2021.
The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil, Czech Republic (formerly Praha Vaccines), as well as at the following partnered manufacturing sites:
Novavax Matrix-M adjuvant is now being manufactured at Novavax AB in Uppsala, Sweden and the following partnered manufacturing sites:
Signing of the manufacturing agreement with Novavax for NVX-CoV2373 is another great milestone for both companies, which will further strengthen our existing relationship. SIIPL expertise to scale-up and manufacture NVX-CoV2373 will help ensure the supply of this most-needed vaccine, said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.
About NVX-CoV2373
NVXCoV2373 is a vaccine candidate engineered from the genetic sequence of SARSCoV2, the virus that causes COVID-19 disease. NVXCoV2373 was created using Novavax recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVXCoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 portion of the Phase 1/2 clinical trial, NVXCoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Phase 2 clinical trials began in August 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
About Matrix-M
Novavax patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.
About Serum Institute of India
Serum Institute of India Pvt. Ltd. was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics. Serum is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe.
Serum is ranked as India's No. 1 biotechnology company, manufacturing highly specialized lifesaving biologics like vaccines using cutting edge genetic and cell-based technologies, antisera and other medical specialties.
The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.
Learn more about Serum Institute of India at https://www.seruminstitute.com/.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil society organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 9 partnerships to develop vaccines against the novel coronavirus. The programs will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.
Before the emergence of COVID-19 CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
Novavax Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading Risk Factors in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 8-K for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Novavax
InvestorsSilvia Taylor and Erika Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659
- First cow to produce human insulin in its milk created in Brazil - Cosmos - March 18th, 2024
- Engineering the Microbiome: CRISPR Leads the Way - The Scientist - March 18th, 2024
- The de-extinction process to bring woolly mammoths back to life - The Week - March 18th, 2024
- CRISPR gene editing applications are expanding dramatically in agriculture. Here are the latest advances - Genetic Literacy Project - March 18th, 2024
- Polymerase Chain Reaction (PCR) - National Human Genome Research Institute - March 18th, 2024
- Colossal Genetic Breakthrough Could Be the Key to Reviving Wooly Mammoths - Syfy - March 18th, 2024
- Breaking: Crop gene editing greenlighted by European Parliament. Fight over labeling looms as measure moves to the ... - Genetic Literacy Project - February 10th, 2024
- GMOs on the spotlight in East Africa again - The Citizen - February 10th, 2024
- Blog: Let's Not Ignore the Science in the Fight Against Malaria - chimpreports.com - February 10th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic Modification Techniques and Applications - Technology Networks - January 9th, 2024
- Transformation-associated recombination (TAR) cloning and its applications - EurekAlert - January 9th, 2024
- Are GMOs Safe? The Benefits of Science-Enhanced Foods | TIME - TIME - January 9th, 2024
- Here's the skinny on fast-emerging genetic engineering tools that are rapidly improving global farming - Genetic Literacy Project - January 9th, 2024
- What Fruit Looked Like 100 Years Ago, Before Genetic Modification - Green Matters - January 9th, 2024
- APHIS Reopens Comment Period on Proposed Additional Exemptions for Plants Modified or Produced Through Genetic Engineering - The National Law Review - January 9th, 2024
- Restriction Enzyme Market is set to Reach US$ 647.41 million at a CAGR of 5.7% from the forecast period 2023 to ... - GlobeNewswire - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Star Trek: Julian Bashir's Tale of Genetic Engineering and the Complexity of Parental Acceptance - GameRant - December 13th, 2023
- How to Improve Livestock Health, and Cut - Breakthrough Institute - December 13th, 2023
- Opinion | The Genetically-Engineered Tree That Never Was - Common Dreams - December 13th, 2023
- Genome Editing Market Size and Share to Surpass USD 14.5 billion by 2035 | Roots Analysis - Yahoo Finance - December 13th, 2023
- Dallas-Based Colossal Biosciences Aims to De-Extinct the Woolly Mammoth - The Texan - December 13th, 2023
- Revolutionizing probiotic therapy: The emergence of CRISPR-Cas engineered strains - Medical Xpress - December 13th, 2023
- Genetically engineered cell therapies with mRNA lipid nanoparticles for transferrable platelets - Phys.org - December 13th, 2023
- 'Perhaps GMOs are closer to natural processes than we think': How genetic modification mimics natural evolution of ... - Genetic Literacy Project - December 13th, 2023
- Advancements in Genome Editing and CRISPR-Cas9 Technology - Medriva - December 13th, 2023
- Gene Therapy: Unlocking Innovations in Cancer Treatment, Detection, and Drug Development - Securities.io - December 13th, 2023
- Mayo Clinic Research on Genetically Engineered Virus and CAR-T Cell Therapy for Liver Cancer - Medriva - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021
- Gene editing, joke theft and manifesting - The Week UK - October 5th, 2021
- Opinion: Saving lives through real social justice - Agri-Pulse - October 5th, 2021
- What is biohacking? - News Anyway - October 5th, 2021
- Science, business and the humanities: CP Snow's 'Two Cultures' sixty years on - TheArticle - October 5th, 2021
- Probiotic Yeast Engineered To Produce Beta-Carotene - Technology Networks - April 17th, 2021
- In the US, Imminent Release of Genetically Modified Mosquitoes To Fight Dengue - The Wire Science - April 17th, 2021
- CRISPRoff: A New Addition to the CRISPR Toolbox - Technology Networks - April 17th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 17th, 2021
- Grammar of the Genome: Reading the Influence of DNA on Disease - Baylor University - April 17th, 2021
- We cannot let China set the standards for 21st century technologies | TheHill - The Hill - April 17th, 2021
- First GMO Mosquitoes to Be Released in the Florida Keys - Singularity Hub - April 17th, 2021
- Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations - BioSpace - April 17th, 2021
- AmunBio and NorthShore University to Advance Cancer Immunotherapy with Engineered Oncolytic Viruses - OncoZine - April 17th, 2021
- StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - BioSpace - April 17th, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 17th, 2021
- EU's refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal - Alliance for Science - Alliance for Science - February 14th, 2021